Table 1 The clinicopathological features between VISTA-high group and VISTA-low group based on Total regions.
From: Immunosuppressive immune microenvironment landscapes in VISTA-high gastric cancer
Characteristic | All | High Group | Low Group | P value |
|---|---|---|---|---|
N = 172 | N = 52 | N = 120 | ||
Age | 0.326 | |||
median, IQR | 62.00 [53.00, 69.00] | 62.50 [53.75, 71.00] | 62.00 [52.75, 68.00] | |
Gender | 0.396 | |||
Male | 130 (75.6%) | 42 (80.8%) | 88 (73.3%) | |
Female | 42 (24.4%) | 10 (19.2%) | 32 (26.7%) | |
ECOG PS | 0.555 | |||
0 | 73 (42.4%) | 26 (50.0%) | 47 (39.2%) | |
1 | 87 (50.6%) | 24 (46.2%) | 63 (52.5%) | |
2 | 3 (1.7%) | 1 (1.9%) | 2 (1.7%) | |
3 | 2 (1.2%) | 0 (0.0%) | 2 (1.7%) | |
Unknown | 7 (4.1%) | 1 (1.9%) | 6 (5.0%) | |
Location | 0.735 | |||
GEJ | 58 (33.7%) | 19 (36.5%) | 39 (32.5%) | |
non-GEJ | 114 (66.3%) | 33 (63.5%) | 81 (67.5%) | |
Differentiation | 0.484 | |||
Moderate | 57 (33.1%) | 20 (38.5%) | 37 (30.8%) | |
Moderate-poor | 39 (22.7%) | 8 (15.4%) | 31 (25.8%) | |
Poor | 73 (42.4%) | 23 (44.2%) | 50 (41.7%) | |
Unknown | 3 (1.7%) | 1 (1.9%) | 2 (1.7%) | |
Lauren classification | 0.676 | |||
Intestinal type | 107 (62.2%) | 33 (63.5%) | 74 (61.7%) | |
Diffuse type | 27 (15.7%) | 10 (19.2%) | 17 (14.2%) | |
Mixed type | 35 (20.3%) | 8 (15.4%) | 27 (22.5%) | |
Unknown | 3 (1.7%) | 1 (1.9%) | 2 (1.7%) | |
Stage | 0.008 | |||
II | 1 (0.6%) | 1 (1.9%) | 0 (0.0%) | |
III | 30 (17.4%) | 15 (28.8%) | 15 (12.5%) | |
IV | 138 (80.2%) | 34 (65.4%) | 104 (86.7%) | |
Unknown | 3 (1.7%) | 2 (3.8%) | 1 (0.8%) | |
HER2 expression | 0.307 | |||
Positive | 102 (59.3%) | 31 (59.6%) | 71 (59.2%) | |
Negative | 69 (40.1%) | 20 (38.5%) | 49 (40.8%) | |
Unknown | 1 (0.6%) | 1 (1.9%) | 0 (0.0%) | |
PD-L1 expression (CPS) | 0.478 | |||
<1 | 42 (24.4%) | 15 (28.8%) | 27 (22.5%) | |
1-5 | 28 (16.3%) | 7 (13.5%) | 21 (17.5%) | |
5-10 | 24 (14.0%) | 7 (13.5%) | 17 (14.2%) | |
>10 | 47 (27.3%) | 17 (32.7%) | 30 (25.0%) | |
Unknown | 31 (18.0%) | 6 (11.5%) | 25 (20.8%) | |
MMR status | 0.204 | |||
pMMR | 153 (89.0%) | 48 (92.3%) | 105 (87.5%) | |
dMMR | 12 (7.0%) | 4 (7.7%) | 8 (6.7%) | |
Unknown | 7 (4.1%) | 0 (0.0%) | 7 (5.8%) | |
EBV status | 0.626 | |||
Positive | 18 (10.5%) | 7 (13.5%) | 11 (9.2%) | |
Negative | 145 (84.3%) | 43 (82.7%) | 102 (85.0%) | |
Unknown | 9 (5.2%) | 2 (3.8%) | 7 (5.8%) | |
Therapy Category | 0.062 | |||
First-line | 115 (66.9%) | 31 (59.6%) | 84 (70.0%) | |
Second-line or Above | 36 (20.9%) | 10 (19.2%) | 26 (21.7%) | |
Neoadjuvant Therapy | 21 (12.2%) | 11 (21.2%) | 10 (8.3%) |
